Survival in the transplant group was also similar to a cohort of non-cancer patients who underwent lung transplantation for ...
Unresectable stage III non–small cell lung cancer (NSCLC) represents a biologically and clinically heterogeneous group of tumors. Concurrent chemoradiotherapy (cCRT) has long been the cornerstone of ...
Background Sociodemographic inequalities impact patients with non-small cell lung cancer (NSCLC). Advances in novel ...
Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2. This is an ...
CRT improved OS and CSS in elderly patients with stage II non-surgical NSCLC compared to RT alone. The study used the SEER database, including patients diagnosed from 2010 to 2017, with 1746 patients ...
As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps when testing is negative for NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results